Rubius Therapeutics (RUBY) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Rubius Therapeutics (RUBY) Tops Q4 EPS by 4c

Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity

March 12, 2020 7:01 AM EDT

RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA

Internal cGMP Manufacturing Ready to Support Upcoming Oncology Clinical Trials

Cash Runway Extended into 2022

Conference Call Scheduled for Today at 8:00 a.m. EST

CAMBRIDGE, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY) a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported fourth quarter and... More